ReviewDisease models & mechanisms2019
Modeling blood diseases with human induced pluripotent stem cells.
Review in Disease models & mechanisms, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Modeling myeloid cell development in health and disease using induced pluripotent stem cells.Frontiers in immunology · 2026Review
- Advances in the characterization of in vitro-generated red blood cells: from biophysical properties to functional applications.Stem cell research & therapy · 2025Review
- Utilization of Stem Cells in Medicine: A Narrative Review.International journal of molecular sciences · 2025Review
- Article
- Article
- Recent updates of stem cell-based erythropoiesis.Human cell · 2023Review
- In vitro erythrocyte production using human-induced pluripotent stem cells: determining the best hematopoietic stem cell sources.Stem cell research & therapy · 2023Article
- Using Pluripotent Stem Cells to Understand Normal and Leukemic Hematopoietic Development.Stem cells translational medicine · 2022Review
- Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs.Blood advances · 2022Article
- iMyoblasts for ex vivo and in vivo investigations of human myogenesis and disease modeling.eLife · 2022Article
- Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Review
- Harnessing organs-on-a-chip to model tissue regeneration.Cell stem cell · 2021Review
- Development, characterization, and hematopoietic differentiation of Griscelli syndrome type 2 induced pluripotent stem cells.Stem cell research & therapy · 2021Article
- Direct Generation of Immortalized Erythroid Progenitor Cell Lines from Peripheral Blood Mononuclear Cells.Cells · 2021Article
- Direct Comparison of Four Hematopoietic Differentiation Methods from Human Induced Pluripotent Stem Cells.Stem cell reports · 2020Article
- From blood development to disease: a paradigm for clinical translation.Disease models & mechanisms · 2020Article
- Mechanistic and Translational Advances Using iPSC-Derived Blood Cells.Journal of Experimental Pathology · 2020Article
- Modeling Leukemia with Human Induced Pluripotent Stem Cells.Cold Spring Harbor perspectives in medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Induced pluripotent stem cells (iPSCs) are derived from somatic cells through a reprogramming process, which converts them to a pluripotent state, akin to that of embryonic stem cells. Over the past decade, iPSC models have found increasing applications in the study of human diseases, with blood disorders featuring prominently. Here, we discuss methodological aspects pertaining to iPSC generation, hematopoietic differentiation and gene editing, and provide an overview of uses of iPSCs in modeling the cell and gene therapy of inherited genetic blood disorders, as well as their more recent use as models of myeloid malignancies. We also discuss the strengths and limitations of iPSCs compared to model organisms and other cellular systems commonly used in hematology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.